Physician

Rafael Lupercio, M.D.

According to 2025 Medicare claims, Rafael Lupercio, M.D. (NPI: 1174532618) practices pulmonary disease in the Redding, CA market, with the plurality of this provider's patient population coming from Shasta, CA. This provider's primary affiliated billing organization is SHASTA CRITICAL CARE SPECIALISTS MEDICAL CLINIC, INC. (NPI: 1245249770; TIN: 20-1811944) and primary practice location at 96001-0228. Lupercio is affiliated with the PSW ACO (ACO ID: A5323), participating under the MSSP model.

Lupercio's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,331 traditional Medicare patients, billed 9,897 HCPCS/CPT codes, and received $635,797 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,548 prescription claims across 562 beneficiaries totaling $1,987,531 in drug costs, led by Ofev (Nintedanib Esylate). DME data shows 2,267 claims. Open Payments data shows 797 records totaling $3,913,868. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,005,843 to $1,987,531. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,069	12,942	$771,616
2016	2,285	14,947	$874,312
2017	2,353	16,172	$852,654
2018	2,269	14,452	$767,448
2019	2,536	14,497	$865,046
2020	2,444	12,023	$740,183
2021	2,258	10,752	$704,237
2022	2,329	10,716	$636,241
2023	2,457	10,589	$645,632
2024	2,331	9,897	$635,797

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	420	1,681	$1,005,843
2016	537	2,424	$1,489,702
2017	562	2,763	$1,812,523
2018	561	2,832	$1,501,327
2019	603	2,877	$1,546,345
2020	620	3,251	$2,083,943
2021	635	2,952	$1,776,276
2022	594	2,662	$1,962,580
2023	599	2,597	$2,404,200
2024	562	2,548	$1,987,531

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	335	1,755	$143,963
2016	418	2,081	$142,967
2017	545	2,441	$176,501
2018	674	3,297	$330,304
2019	708	3,296	$351,668
2020	831	4,128	$472,147
2021	803	3,983	$478,274
2022	598	3,202	$225,539
2023	483	2,441	$180,178
2024	461	2,267	$165,591

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,570	2,639	$96
94729	Test to examine how well the lungs exchange gases	1,013	1,069	$44
94726	Test to determine lung volumes using sensors	1,002	1,057	$42
94060	Test to measure expiratory airflow and volume changes before and after medication administration	651	658	$28
94664	Evaluation of use of breathing device	636	643	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ofev	Nintedanib Esylate	40	1,200	$478,760
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	289	18,060	$364,962
Opsumit	Macitentan	12	360	$151,525
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	151	7,700	$148,927
Prolastin C	Alpha-1-Proteinase Inhibitor	13	343	$115,273

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	59	$50,459
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	78	577	$43,484
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	39	$31,076
E1392	Portable oxygen concentrator, rental	Y	42	277	$9,509
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	72	237	$5,734

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	37	$1,289	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	760	$3,912,579	ModernaTX, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rafael Lupercio, M.D.?

Tedicare shows public-source Medicare data for Rafael Lupercio, M.D. (NPI 1174532618), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rafael Lupercio, M.D. have ACO affiliation data?

Rafael Lupercio, M.D. is shown with ACO affiliation data for PSW ACO (MSSP, ACO ID A5323).

What billing organization is linked to Rafael Lupercio, M.D.?

Rafael Lupercio, M.D. is linked to SHASTA CRITICAL CARE SPECIALISTS MEDICAL CLINIC, INC. (billing NPI 1245249770) in the available physician profile data.

Does Rafael Lupercio, M.D. have Open Payments data?

Rafael Lupercio, M.D. has 797 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.